US Corporate Distress Financial Stress SEC Filings — October 19, 2026

Preliminary Q3 2026 revenue of ~$1.22M, up 256% QoQ from ~$344K, driven by August 2026 REZENOPY launch and first wholesale shipments; Arbli wholesale units up 74% sequentially; management targets profitability in 2027 but figures are unaudited

Going-concern doubt and dilution risk flagged in the company's own forward-looking risk factors despite the revenue inflection, signaling that top-line momentum is not yet funding-neutral

Nasdaq Staff Determination under Rule 5810(c)(3)(A)(iii) after ten consecutive days at or below $0.10 mandates delisting; trading suspension and delisting of common stock and warrants set for the open on October 23, 2026

CFO Udaychandra Devasper resigned effective October 23, 2026, coinciding with delisting, a leadership-depth signal that management is departing into the distress event

Board exploring headcount reductions, possible suspension of SEC reporting, and strategic alternatives including sale or merger, indicating a shift from growth to asset-preservation mode

Reliance on lender credit arrangements with security interests over assets raises collateral and covenant risk if revenue ramp slips before profitability in 2027

Market value of listed securities deficiency (notice dated April 24, 2026) had a compliance deadline of October 21, 2026, which is now superseded by the accelerated delisting trigger, confirming the compliance path closed without a cure

The Q3 2026 revenue print was filed under Item 2.02 alongside Item 3.01 Nasdaq disclosure, meaning the company is both reporting growth and managing a listing deficiency simultaneously, a mixed signal for credibility

Common stock and warrants suspended and delisted at the open on October 23, 2026; the Nasdaq rule trigger is mechanical, so a hearing request does not stop the suspension

Board is evaluating suspension of SEC reporting obligations, which would reduce investor disclosure and price transparency for remaining holders

CFO resignation effective October 23, 2026 at the same time as delisting, leaving financial reporting capacity at its weakest point during any wind-down or sale process

Stock at or below $0.10 for ten sessions implies minimal equity value to common and warrant holders; any sale or merger outcome is uncertain and may be dilutive or zero-recovery

Company's own filing flags substantial doubt about continuing as a going concern, meaning revenue growth from a small base (~$1.22M quarterly) does not yet cover the cost structure

Q3 2026 revenue is preliminary and unaudited; full figures in the Form 10-Q may be adjusted, so the reported 256% sequential jump could be revised

Filing explicitly warns of dilution from future funding, which would be needed to bridge to the 2027 profitability target, pressuring per-share value

Filing references Item 3.01 and the ability to maintain Nasdaq listing as a live risk, meaning Scienture may face a delisting path similar to Stardust if equity price or compliance issues persist

Security interests under credit arrangements mean lenders have priority claims on assets in any restructuring, subordinating equity holders

Q3 2026 revenue up 256% QoQ on the August launch and first wholesale shipments; if the 10-Q confirms the preliminary figures, the commercial trajectory supports the 2027 profitability target

Arbli wholesale unit sales up 74% sequentially, showing product-level demand beyond the REZENOPY launch and diversifying revenue sources

Audited-quality confirmation in the upcoming Form 10-Q could re-rate the equity if revenue holds and the going-concern language softens

Board is actively exploring strategic alternatives including sale or merger; a control transaction could deliver value above the depressed market price for remaining holders, though no assurance is given

Forced selling into the October 23 suspension may create dislocation in SDST and SDSTW; investors with a view on recovery value versus liquidation could assess the warrant and common pricing post-delisting

Among these two names, Scienture shows the only revenue inflection, making it the relative-performance outlier against the more acute Stardust distress profile

Stardust's ten-day sub-$0.10 trigger under Rule 5810(c)(3)(A)(iii) bypasses the usual 180-day compliance window, showing the exchange will delist sub-penny issuers without extended cure periods; this raises delisting risk for other micro-cap names trading near the threshold

Scienture shows that early commercial revenue ramps (256% QoQ) can coexist with substantial going-concern doubt, a pattern common among launch-stage specialty pharma and medtech issuers that need funding to reach breakeven

Stardust's CFO resignation coinciding with delisting and strategic review fits a wider pattern in which finance leadership exits as distress peaks, reducing reporting quality precisely when disclosure matters most

Both filings reference security interests and credit arrangements, indicating that senior secured debt will limit equity recovery in distress; equity holders should treat lender claims as the first constraint in any scenario

Decision on requesting a Nasdaq Hearings Panel review, $20,000 fee, due 4:00 p.m. ET, October 23, 2026; hearing will not stay suspension, so the outcome is mainly a question of relisting optionality

Suspension and delisting of common stock and warrants at market open, October 23, 2026; monitor OTC migration and any SEC reporting suspension announcement

Board exploring sale or merger, headcount reductions, and potential suspension of SEC reporting; any 8-K on a transaction or wind-down would be material

Udaychandra Devasper's resignation effective October 23, 2026; watch for interim CFO appointment and any filing gaps

Full results will confirm or adjust the preliminary ~$1.22M revenue and 256% QoQ growth, and will update going-concern language; key for validating the commercial thesis

Item 3.01 disclosure indicates an active listing issue; monitor for any Staff Determination, compliance plan, or delisting notice in the coming weeks

Any equity raise or debt amendment would signal dilution magnitude and whether the 2027 profitability target is funded

Next revenue run-rate after the August REZENOPY launch will show whether the 256% QoQ jump is sustainable or a launch-stocking effect